P609: Uncertain usefulness of infliximab trough levels for therapeutic decision-making in inflammatory bowel disease patients on infliximab maintenance therapyECCO '18 Vienna
2018
P610: Risk of active Hepatitis B and C infections in the Phases 2 and 3 clinical trial programmes for ustekinumabECCO '18 Vienna
2018
P611: Outcome in ulcerative colitis after switch from subcutaneous anti-TNF to intravenous anti-TNF: A multicentre studyECCO '18 Vienna
2018
P613: Predictors of treatment persistence in ulcerative colitis patients treated with golimumab: A multicentre cohort studyECCO '18 Vienna
2018
P615: Efficacy of vedolizumab in patients with Crohn's disease may differ depending on the disease location: The UCLH experienceECCO '18 Vienna
2018
P616: Utility of zinc protoporphyrin/haem ratio as a marker of iron deficiency with or without anaemia in patients with inflammatory bowel diseaseECCO '18 Vienna
2018
P617: Single-centre experience with biological treatment in budesonide-refractory microscopic colitis patientsECCO '18 Vienna
2018
P618: Post-operative pain following laparoscopic right hemicolectomy for Crohn’s disease a comparative studyECCO '18 Vienna
2018
P619: Systematic review: Psychosocial factors associated with pain in inflammatory bowel diseaseECCO '18 Vienna
2018
P621: Faecal calprotectin after the induction of anti-TNF therapy predicts mucosal healing in patients with ulcerative colitis: A prospective single-centre studyECCO '18 Vienna
2018
P623: Quality of life as predictor of biological levels decay in inflammatory bowel diseasesECCO '18 Vienna
2018
P624: Vedolizumab can induce clinical remission in patients with chronic antibiotic-refractory pouchitis: A retrospective single-centre experienceECCO '18 Vienna
2018
P625: A prospective study to assess the effectiveness of tacrolimus therapy in ulcerative colitisECCO '18 Vienna
2018